Tag - OCUL

Developments

Ocular Therapeutix doses first patients in Phase 2 dry eye disease trial

Ocular Therapeutix (NASDAQ:OCUL) dosed the first patients in its Phase 2 trial evaluating OTX-CSI for the treatment of dry eye disease. The trial will enroll some 105 patients who will receive either one of two...

September 29, 2020

Developments

Ocular Therapeutix doses first patient in Phase 3 allergic conjunctivitis trial

Ocular Therapeutix (NASDAQ:OCUL) has dosed the first patients in its Phase 3 efficacy trial of DEXTENZA for the treatment of symptoms of allergic conjunctivitis (AC). DEXTENZA is a corticosteroid that is FDA-approved...

September 24, 2019

Feature

Ocular Therapeutix eyeing sustained drug delivery

By Len Zehr Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to...

March 17, 2015

Tag - OCUL

Ocular Therapeutix doses first patients in Phase 2 dry eye disease trial

Ocular Therapeutix doses first patient in Phase 3 allergic conjunctivitis trial

Ocular Therapeutix eyeing sustained drug delivery

General

More